Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Rating) have received an average rating of “Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have covered the stock in the last year is $13.75.
A number of research firms recently commented on CABA. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Cabaletta Bio in a report on Monday, May 16th. Mizuho decreased their target price on Cabaletta Bio from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 25th. Finally, Zacks Investment Research raised Cabaletta Bio from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Wednesday, May 25th.
Several hedge funds have recently bought and sold shares of the company. Samlyn Capital LLC boosted its position in shares of Cabaletta Bio by 295.8% during the fourth quarter. Samlyn Capital LLC now owns 1,383,381 shares of the company’s stock worth $5,243,000 after buying an additional 1,033,906 shares during the period. Vanguard Group Inc. boosted its position in shares of Cabaletta Bio by 16.3% during the first quarter. Vanguard Group Inc. now owns 1,051,838 shares of the company’s stock worth $2,135,000 after buying an additional 147,346 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Cabaletta Bio by 5.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,000 shares of the company’s stock worth $3,601,000 after buying an additional 50,000 shares during the period. BlackRock Inc. boosted its position in shares of Cabaletta Bio by 52.6% during the fourth quarter. BlackRock Inc. now owns 504,190 shares of the company’s stock worth $1,910,000 after buying an additional 173,709 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Cabaletta Bio by 20.2% during the fourth quarter. Victory Capital Management Inc. now owns 264,224 shares of the company’s stock worth $1,002,000 after buying an additional 44,438 shares during the period. 62.75% of the stock is owned by institutional investors.
Cabaletta Bio (NASDAQ:CABA – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.08. As a group, equities research analysts predict that Cabaletta Bio will post -2.07 earnings per share for the current fiscal year.
About Cabaletta Bio (Get Rating)
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- Get a free copy of the StockNews.com research report on Cabaletta Bio (CABA)
- Expedia Group: Recovering with the Travel Industry
- It’s Time To Grab The Lovesac Company By The Shorts
- Lightning Strikes For Thor Industries
- Asana posts a strong result, what you should consider before buying the stock?
- The Insiders And Analysts Buy Academy Sports + Outdoors
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.